Analysis of point mutations in the hprt gene of cancer patients treated with radioimmunoglobulin therapy.
The mutagenic impact of various environmental and therapeutic agents can now be directly assayed in humans by the T-lymphocyte cloning assay. We have previously reported that following radioimmunoglobulin therapy, cancer patients exhibited increased mutant frequency of the hprt locus and an increased yield of large intergenic deletions compared to unexposed controls. Here we report the results of the analysis of 26 independent hprt mutations in nine cancer patients who underwent radioimmunoglobulin therapy. The majority of mutations (52%) had lost exon sequences from the mRNA. The remaining mutations were 20% small deletions and frameshifts and 28% base substitutions. The type of mutations observed were similar to those seen in unexposed controls. The site distribution of the mutations, however, indicates that some sequence contexts may be more sensitive to radiation mutagenesis than others.
Skandalis
A
A
Center for Environmental Health, University of Victoria, British Columbia, Canada.
Curry
J
J
O'Neill
J P
JP
Nicklas
J A
JA
Albertini
R J
RJ
Glickman
B W
BW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001483:Base Sequence; D005091:Exons; D005260:Female; D016368:Frameshift Mutation; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000201:enzymology / Q000532:radiotherapy*; D017354:Point Mutation; D016499:Radioimmunotherapy / Q000009:adverse effects*; D013601:T-Lymphocytes / Q000201:enzymology*
D007041:Hypoxanthine Phosphoribosyltransferase